|
GENUV selects Korea Investment & Securities Co.,Ltd. as IPO lead underwriter
With steady advancement in the research field of neurodegenerative diseases and immuno-oncology, GENUV aims to go public on KOSDAQ through the Technology Special Listing track.
As an early-stage biopharma company discovering and developing innovative therapeutics for highly debilitating CNS disease and cancer, the company announced its selection of Korea Investment & Securities Co.,Ltd. as the lead underwriter for its initial public offering on KOSDAQ.
GENUV aims to go public on KOSDAQ this year through the Technology Special Listing track and with the lead underwriter in place, is making preparations for embarking on the IPO journey.
GENUV is developing therapeutics to treat neurodegenerative diseases such as ALS(Lou Gehrig’s disease) and Alzheimer’s disease through new approaches based on the novel mode of action of neural regeneration and neural homeostasis in addition to “ATRIVIEW®”, an in-house-developed screening platform for the discovery of new drugs.
Furthermore, the company is validating and developing the innovative antibody drug discovery platforms ‘SHINE MOUSE®’ and ‘GENUV MOUSE TM’ along with multiple new antibody drug candidates, including PD-1 antibody, for the development of immuno-oncology treatment.
With these solid developments in progress, GENUV has raised an additional 12.5 billion won between Nov-Dec 2020 via Pre-Series C funding.
....
(Translated by GENUV)
To view original article, please click here.
|
